Overview

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Status:
Not yet recruiting

Trial end date:
2025-01-08

Target enrollment:

Participant gender:

Summary

To learn if adding a new medication, IM156, to treatment with gemcitabine and nab-paclitaxel is safe and tolerable. The ability of this combination to improve the success of this treatment for these patients will also be studied.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel